Evidence map›Paper›PMID 28945790›Full record

ArticlePLoS pathogens2017

A single gp120 residue can affect HIV-1 tropism in macaques.

Gregory Q Del Prete, Brandon F Keele, Jeannine Fode, Keyur Thummar, Adrienne E Swanstrom, Anthony Rodriguez, Alice Raymond, Jacob D Estes, Celia C LaBranche, David C Montefiori and 4 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Journal of virology · 2019
    Article
  16. Article
  17. Article
  18. Article
  19. Derivation of simian tropic HIV-1 infectious clone reveals virus adaptation to a new host.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Gregory Q Del PreteAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, United States of America.ORCID http://orcid.org/0000-0001-6180-5361
Brandon F KeeleAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, United States of America.ORCID http://orcid.org/0000-0002-2381-1151
Jeannine FodeLaboratory of Retrovirology, The Rockefeller University, New York, NY, United States of America.
Keyur ThummarLaboratory of Retrovirology, The Rockefeller University, New York, NY, United States of America.ORCID http://orcid.org/0000-0003-3430-235X
Adrienne E SwanstromAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, United States of America.ORCID http://orcid.org/0000-0003-0429-4213
Anthony RodriguezLaboratory of Retrovirology, The Rockefeller University, New York, NY, United States of America.ORCID http://orcid.org/0000-0001-6816-5870
Alice RaymondLaboratory of Retrovirology, The Rockefeller University, New York, NY, United States of America.ORCID http://orcid.org/0000-0002-3148-9764
Jacob D EstesAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, United States of America.
Celia C LaBrancheDepartment of Surgery, Duke University Medical Center, Durham, NC, United States of America.ORCID http://orcid.org/0000-0002-6653-6655
David C MontefioriDepartment of Surgery, Duke University Medical Center, Durham, NC, United States of America.
Vineet N KewalRamaniCenter for Cancer Research, National Cancer Institute, Frederick, MD, United States of America.
Jeffrey D LifsonDepartment of Surgery, Duke University Medical Center, Durham, NC, United States of America.ORCID http://orcid.org/0000-0002-9494-0268
Paul D BieniaszLaboratory of Retrovirology, The Rockefeller University, New York, NY, United States of America.ORCID http://orcid.org/0000-0002-2368-3719
Theodora HatziioannouLaboratory of Retrovirology, The Rockefeller University, New York, NY, United States of America.ORCID http://orcid.org/0000-0002-7889-0766
Rockefeller University · USLeidos (United States) · USDuke Medical Center · USHoward Hughes Medical Institute · USNational Cancer Institute · US

Funding

Overcoming Host Restriction Factors to Develop Better Animal Models for HIV/AIDS.R01AI078788 · NIAID · ROCKEFELLER UNIVERSITY · PI HATZIIOANNOU, THEODORA · 2008 to 2021
$9.3M
Discovery and Mechanism of Antiretroviral FactorsR37AI064003 · NIAID · ROCKEFELLER UNIVERSITY · PI BIENIASZ, PAUL D. · 2011 to 2020
$4.9M
Retrovirus Restriction by Trima5alphaR01AI064003 · NIAID · AARON DIAMOND AIDS RESEARCH CENTER · PI BIENIASZ, PAUL D. · 2005 to 2009
$2.1M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS R01 AI064003NIAID NIH HHS R01 AI078788NIAID NIH HHS R37 AI064003
6 · The paper itself

Abstract

Species-dependent variation in proteins that aid or limit virus replication determines the ability of lentiviruses to jump between host species. Identifying and overcoming these differences facilitates the development of animal models for HIV-1, including models based on chimeric SIVs that express HIV-1 envelope (Env) glycoproteins, (SHIVs) and simian-tropic HIV-1 (stHIV) strains. Here, we demonstrate that the inherently poor ability of most HIV-1 Env proteins to use macaque CD4 as a receptor is improved during adaptation by virus passage in macaques. We identify a single amino acid, A281, in HIV-1 Env that consistently changes during adaptation in macaques and affects the ability of HIV-1 Env to use macaque CD4. Importantly, mutations at A281 do not markedly affect HIV-1 Env neutralization properties. Our findings should facilitate the design of HIV-1 Env proteins for use in non-human primate models and thus expedite the development of clinically relevant reagents for testing interventions against HIV-1.

Indexed as

Adaptation, PhysiologicalAnimalsCD4 AntigensDisease Models, AnimalFemaleFlow CytometryHIV-1HIV Envelope Protein gp120HIV InfectionsHumansImmunoblottingMacaca mulattaMalePolymerase Chain ReactionSimian Immunodeficiency VirusViral TropismCD4 Antigensgp120 protein, Human immunodeficiency virus 1HIV Envelope Protein gp120

Identifiers

PMID28945790
PMCPMC5629034
OpenAlexW2756541019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.